Get the Stockscreener App
53.77
0.89%
0.26
Bright Minds Biosciences Inc stock is traded at $53.77, with a volume of 28,410.
It is up +0.89% in the last 24 hours and down -32.09% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$53.51
Open:
$53.33
24h Volume:
28,410
Relative Volume:
0.16
Market Cap:
$521.81M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-22.01
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-11.47%
1M Performance:
-32.09%
6M Performance:
-27.15%
1Y Performance:
+3.12%
1-Day Range:
$53.00
$54.37
1-Week Range:
$52.91
$62.45
52-Week Range:
$48.94
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
53.18 | 525.04M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
521.13 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.95 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.22 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.81 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences Inc. (DRUG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 6.9%Here's What Happened - MarketBeat
Bright Minds Biosciences Slides Under Pressure: Pre-Revenue Cash Burn and Insider Selling Weigh on Clinical-Stage Sentiment - kalkine.ca
Earnings Calendar for: - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Rating Lowered by Zacks Research - MarketBeat
WHY Goldsky Resources (TSXV:GSKR), Dexterra Group (TSX:DXT), Bright Minds Biosciences (CN:DRUG), Magna Mining (TSX:NICU) and ADENTRA (TSX:ADEN) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Top 10 Best Biotech Companies In Canada 2026 - Nubia Magazine!
Bright Minds Biosciences to Present at Upcoming Conferences - The Manila Times
Bright Minds Biosciences Stock Slides 4.82% as Biotech Volatility Bites: Is More Downside Pressure Ahead for CN:DRUG? - kalkine.ca
Bright Minds Biosciences Faces Fresh Pressure as Clinical Execution Risk Weighs on Sentiment - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 5.2%Time to Sell? - MarketBeat
Braidwell LP Decreases Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Stock Falls 3.06%: CN:DRUG Faces Correction Pressure as Clinical and Valuation Risks Test Sentiment - kalkine.ca
Bright Minds Biosciences Inc (DRUG) Peer Comparison – Compare with Others - Value Research
Aptose Biosciences Inc. (APTO) Peer Comparison – Compare with Others - Value Research
DRUG: Bright Minds Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bright Minds Biosciences Inc (DRUG) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bright Minds Biosciences Stock Falls 3.85%: Is CN:DRUG Facing Renewed Biotech Volatility as Clinical Risks Remain? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure as Biotech Sentiment Weakens - kalkine.ca
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? - Eastern Progress
13% Of This Bright Minds Biosciences Insider's Holdings Were Sold - simplywall.st
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk - kalkine.ca
What is HC Wainwright's Forecast for DRUG FY2026 Earnings? - MarketBeat
Bright Minds Biosciences Slides as Biotech Volatility Returns — What Could Wake the Stock Up? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure — Can Clinical Momentum Offset Rising Correction Risk? - kalkine.ca
Psychedelic: Enveric, Helus, Bright Minds report earnings results - TipRanks
H.C. Wainwright reiterates Bright Minds stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Bright Minds stock rating at buy - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences Stock: An Epilepsy Story Keeps Drawing Biotech Money - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9%Should You Buy? - MarketBeat
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
TD Cowen Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating - Moomoo
Bright Minds Biosciences (DRUG) Earnings Date and Reports 2026 $DRUG - MarketBeat
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - MarketBeat
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Bright Minds Biosciences (DRUG) Slips to $78.00 as Traders Eye Support at $74.1Chart Pattern Alerts - vinanet.vn
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - finance.yahoo.com
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):